Strong prevalence and growth in number of patients suffering from cardiovascular diseases, increasing number of hip and knee replacement surgical procedures, growth in atrial fibrillation, and increasing incidences of deep vein thrombosis (DVT) are the key factors fueling growth of the global anticoagulant market. Anticoagulants are used to prevent formation of blood clots by reacting with the clotting chemicals in the blood.
The anticoagulant reacts either with the vitamin K or thrombin and fibrinogen present in blood to prevent the formation of fibrin, consequently prevents formation of blood clots. Atrial fibrillation is the most prominent factors responsible for the formation of blood clots, strokes and other heart disorders. With increasing number of patients affected with atrial fibrillation or arrhythmic hears, the demand for anticoagulants is growing significantly for prevention and treatment of heart disorders due to atrial fibrillation.
Additionally, growth in number of patients with pulmonary embolism (PE) and deep vein thrombosis (DVT) is the most prominent factor fueling the demand for anticoagulants in the global market. The global anticoagulant market is expected to grow significantly in coming years.
North America contributed the largest share to the global anticoagulants market and is anticipated to be a dominating geography during the forecast period owing to strong prevalence of cardiovascular disorders and increasing number of patients suffering from pulmonary embolism (PE).
Presence of leading drug manufacturers, increasing awareness regarding lifestyle disorder & cardiovascular health, and increasing investment of new product development are anticipated to bolster the growth of the anticoagulant market in North America during the forecast period. Asia Pacific is anticipated to be the fastest growing market during the forecast period owing to increasing investment on expansion of pharmaceutical industry, growth of medical tourism, prevalence of cardiorespiratory disorders, and rising awareness regarding cardiovascular health across major countries.
The report titled “Anticoagulants Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032” wherein 2021 is historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global anticoagulants market.
Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market. For instance, GlaxoSmithKline plc. reported revenues of USD 41,736.8 million in 2019 and the product segment analysis of the company indicates that Pharmaceuticals business segment of the company dominated revenue in 2019.
The global anticoagulants market is segmented based on drug class, route of administration, application, and geography. Based on drug class, the global anticoagulants market is segmented into novel oral anticoagulants (NOACs), heparin & low-molecular-weight heparin (LMWH), vitamin K antagonist, and others. The novel oral anticoagulants (NOACs) are sub-segmented into Eliquis, Bevyxxa, Xarelto, Savaysa & Lixiana, and Pradaxa. Based on route of administration, the global anticoagulants market is segmented into oral anticoagulant and injectable anticoagulant. Based on application, the global anticoagulants market is segmented into atrial fibrillation & heart attack, deep vein thrombosis (DVT), pulmonary embolism (PE), and others. Based on geography, the global Anticoagulants market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment, and would identify the segment of the company focusing on Anticoagulants. Further, market share of prominent companies in the global anticoagulants market would also be estimated.
For instance, GlaxoSmithKline plc. operates through three business segments namely Pharmaceuticals, Vaccines, and Consumer Health. The anticoagulants are delivered under Pharmaceuticals business segment of the company with revenue contribution of US$ 21,705.5 million in 2019.
The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focus of all the anticoagulant companies. The global anticoagulants market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution.
Product portfolio would focus on all the products under the anticoagulants business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global anticoagulants market.
Major players active in the global anticoagulants market include Aspen Holdings, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc. (A Johnson & Johnson company), Pfizer, Inc., Portola Pharmaceuticals, Inc., and Sanofi S.A.
Market Segmentation:
By drug class
- novel oral anticoagulants (NOACs)
- Eliquis
- Bevyxxa
- Xarelto
- Savaysa & Lixiana
- Pradaxa
- heparin & low-molecular-weight heparin (LMWH)
- vitamin K antagonist
- others
By route of administration
- oral anticoagulant
- injectable anticoagulant
By application
- atrial fibrillation & heart attack
- deep vein thrombosis (DVT)
- pulmonary embolism (PE)
- others
By Geography
- North America
- United States
- Canada
- Rest of North America
- Europe
- Germany
- United Kingdom
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- India
- China
- Australia
- Rest of Asia Pacific
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Rest of South America
